SCHEMBL7550

SCHEMBL7550

O=C1c2ccccc2C(=O)N1N1CCC(n2cc3c(nc2=O)[nH]c2ccccc23)C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.34
CYP1A2 P05177 2/20 0.34
PRKCB P05771 1/20 0.34
CYP1A1 P04798 1/20 0.34
CYP1B1 Q16678 1/20 0.34
SIGMAR1 Q99720 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
CA5A P35218 1/20 0.33
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
TSHR P16473 2/20 0.32
HSD17B10 Q99714 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
UTS2R Q9UKP6 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14551 0.80 ADRA1D (0.52) SIGMAR1ALDH1A1ADRA1DADRA1AADRA1B
SCHEMBL13799 0.75 CA5A (0.41) PDE5ACYP1A2CYP1A1CYP1B1CA5A
SCHEMBL12061561 0.75 SLC6A4 (0.43) PDE5ACA5AADRA1DADRA1AADRA1B
SCHEMBL12062415 0.74 CHRM1 (0.48) PDE5AADRB3KDM4EALDH1A1TSHR
SCHEMBL13800 0.74 HTR6 (0.43) CA5AKDM4EALDH1A1TSHRHSD17B10
SCHEMBL7601 0.74 HTR6 (0.43) CA5AKDM4EALDH1A1TSHRHSD17B10
SCHEMBL14077 0.72 SLC6A4 (0.47) ADRA1DADRA1AADRA1BPARP1CYP2C9
SCHEMBL9038 0.71 MEN1 (0.41) PRKCBNPC1RAB9AADRA1APARP1
SCHEMBL13698 0.70 DRD2 (0.37) KDM4EALDH1A1HSD17B10
SCHEMBL13395617 0.66 CA5A (0.50) CYP1A2CA5AKDM4EALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3406613-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME Melinta Therapeutics, Inc. (US) 2018-11-28 EP disclosed
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
EP-2488525-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME Rib-X Pharmaceuticals, Inc. (US) 2012-08-22 EP disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT PDE5A 1900/4885CYP1A2 1366/4885PRKCB 4304/4885
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT PDE5A 1900/4885CYP1A2 1366/4885PRKCB 4304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.